Treatment - The Bloodline with Blood Cancer United Podcast

After being diagnosed with multiple myeloma at age 31, Brice Davis faced challenges that extended far beyond treatment alone. Join us as he talks about balancing fatherhood, navigating mental health struggles, rebuilding after setbacks, and adjusting to life with a chronic blood cancer. Brice reflects on the importance of community, resilience, and focusing on what matters most while creating a fulfilling life after diagnosis.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Adaptive Biotechnologies Corporation; GSK plc; and Johnson & Johnson.

The post Myeloma, Fatherhood, and Moving Forward first appeared on The Bloodline with Blood Cancer United Podcast.

In this episode, four-time Olympic downhill skier AJ Kitt shares his diagnosis of chronic myeloid leukemia (CML) and how revolutionary medical advances transformed an unsettling diagnosis into a manageable part of his everyday life.

AJ opens up about the initial shock of the news, the emotional toll it took on his young family, and how finding CML pioneer, Dr. Brian Druker, restored his confidence amid deep uncertainty. The conversation dives into his treatment with tyrosine kinase inhibitors (TKIs), the vital importance of self-advocacy, and how he continues to thrive as both an athlete and a ski coach. Tune in to hear why AJ believes that access to reliable information is the ultimate game-changer for anyone navigating a new CML diagnosis.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

The post Chronic Myeloid Leukemia (CML): Four Olympics, One Unexpected Diagnosis first appeared on The Bloodline with Blood Cancer United Podcast.

You cannot have progress without research.

In our latest episode, Dr. Jay Yang of the Karmanos Cancer Institute in Detroit, MI, breaks down the essentials of MDS care, from risk-based treatment plans to managing fatigue and exploring promising new therapies. Tune in to find out why the future of MDS treatment is brighter than ever.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Bristol Myers Squibb and Taiho Oncology, Inc.

The post Myelodysplastic Syndromes (MDS): Progress, Possibility, and What’s Next first appeared on The Bloodline with Blood Cancer United Podcast.

When you hear the word “aggressive,” it can feel overwhelming, but in diffuse large B-cell lymphoma (DLBCL), it can also point to something encouraging – a potential cure.

In this episode, we speak with Dr. Jonathon Cohen, of Winship Cancer Institute in Atlanta, GA, about what a DLBCL diagnosis really means, from how this common type of non-Hodgkin lymphoma is identified to current treatment options and emerging therapies. We explain what patients and families need to know about side effects. We also look at new treatments, including CAR T-cell therapy and bispecific antibodies, and the importance of open communication with your care team.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Genmab US, Inc.

The post Diffuse Large B-Cell Lymphoma (DLBCL): Breaking Down an Aggressive Lymphoma first appeared on The Bloodline with Blood Cancer United Podcast.

What does a myelofibrosis (MF) diagnosis really mean, and how does it fit within a group of conditions called myeloproliferative neoplasms, or MPNs? In this episode, we’re joined by Dr. Tania Jain of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, who helps break it all down in a clear and approachable way.

She discusses how myelofibrosis affects the bone marrow, common symptoms to watch for, and how treatment options are tailored to each person. From managing day-to-day challenges to understanding when more advanced treatments may be considered, this conversation focuses on what matters most to patients and families.

As Dr. Jain shares, “every patient writes their own story,” noting that advancing research offers genuine hope.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Takeda Oncology.

The post Myelofibrosis (MF): More Options, More Hope first appeared on The Bloodline with Blood Cancer United Podcast.

Some people with chronic lymphocytic leukemia (CLL) may feel well day to day, but that doesn’t mean life stays the same. In this episode, we hear from Annette Holloway, a clinical psychologist living with CLL, as she shares how her diagnosis, treatment decisions, and side effects have shaped her daily life. Also joining us is Elise Curry, RN, OCN, a Clinical Trial Nurse Navigator at Blood Cancer United’s Clinical Trial Support Center, who helps break down treatment options, side effects, and the importance of communication with your care team.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by AbbVie Inc.; BeOne Medicines; and Genentech, A Member of the Roche Group.

The post Chronic Lymphocytic Leukemia (CLL): Managing Treatment and Finding Balance first appeared on The Bloodline with Blood Cancer United Podcast.

Acute myeloid leukemia (AML) is a complex diagnosis, and it can be difficult to know what to expect in those early conversations after diagnosis. In this episode, we speak with Dr. Rebecca Olin from the University of California, San Francisco (UCSF), who helps explain what AML is and how care is approached today.

Dr. Olin walks us through how doctors evaluate AML, what factors influence treatment decisions, and how therapies – including targeted treatments, stem cell transplant, and clinical trials – are helping improve outcomes and quality of life. We also discuss the importance of supportive care and ongoing research, offering listeners a clearer picture of how AML is treated now and where progress continues to be made.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Astellas Pharma US Inc.; Daiichi Sankyo Inc.; Debiopharm; Genentech, A Member of the Roche Group; and Kura Oncology, Inc.

The post Acute Myeloid Leukemia (AML): New Approaches For A Complex Diagnosis first appeared on The Bloodline with Blood Cancer United Podcast.

A cancer diagnosis in your 20s or 30s can raise questions most people never expect to face so early in life.

In this episode, we speak with Chris Pagliarulo, who was diagnosed with Hodgkin lymphoma at the age of 29, about the medical, emotional, and practical realities of cancer during early adulthood. We explore issues that are especially relevant for adolescent and young adult (AYA) patients, including delayed diagnosis, fertility preservation, treatment side effects, career disruption, relationships, and finding connection with others who understand. While this conversation highlights experiences unique to AYAs, patients and caregivers of all ages may hear pieces of their own experience reflected in what Chris shares.

CLICK HERE to participate in our episode survey.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Merck & Co., Inc.

The post A Young Adult Story: Cancer, Connection, and Life After Treatment first appeared on The Bloodline with Blood Cancer United Podcast.

With so many new advances in acute lymphoblastic leukemia (ALL), understanding today’s treatment landscape can give patients a clearer, more hopeful outlook.

In this episode, we speak with Marlise Luskin, MD of the Dana-Farber Cancer Institute, about what adults should know when facing a diagnosis of acute lymphoblastic leukemia. Dr. Luskin helps listeners understand how ALL develops, how subtypes are identified, and why genetics play an important role in guiding treatment. She discusses current therapies including chemotherapy, targeted agents and immunotherapies including CAR T-cell therapy, as well as how care teams monitor progress and manage side effects. While ALL is a complex disease, patients and caregivers will hear clear explanations, practical information, and meaningful reasons to feel hopeful about the advances shaping ALL care today.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Syndax Pharmaceuticals Inc.

The post Acute Lymphoblastic Leukemia (ALL): The New Tools Shaping Tomorrow first appeared on The Bloodline with Blood Cancer United Podcast.

Multiple myeloma can feel unfamiliar and overwhelming at first, but today’s advances tell a much brighter story.

In this episode, Dr. Andrew Yee of Massachusetts General Hospital explains what myeloma is, how it’s diagnosed, and why new treatment options, from four-drug regimens to CAR T-cell therapy and bispecific antibodies, are transforming patient outcomes. With enthusiasm and relatable analogies, he highlights how patients may progress from periods of significant challenges to reaching a level of stability and well‑being that allows them to live fully. This conversation offers clarity, confidence, and real optimism for anyone navigating myeloma.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by AbbVie Inc.; Bristol Myers Squibb; Genentech, A Member of the Roche Group; GSK plc.; Johnson & Johnson.

The post Facing Multiple Myeloma: A Guide to Choices, Care, and Confidence first appeared on The Bloodline with Blood Cancer United Podcast.